Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- Drug Damage Watchdog Calls for 3rd Party Long-Term Investigation for HPV
May 2, 2018
- PhRMA/EFPIA Deeply Concerned about MOF Pitch on Stringent CEA Application
April 26, 2018
- PhRMA/EFPIA Say Humira, Jevtana, Xarelto Lost Eligibility under New PMP, Innovation Not Appropriately Defined
April 26, 2018
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says
April 20, 2018
- Asian Industry Groups Agree to Use Common Site Master File for Plant Inspections
April 16, 2018
- PhRMA Chief Warns of Serious Implications for Japan Market after 2018 Pricing Reform
April 13, 2018
- Company Category Criteria for Price Maintenance Premium Tough on Ophthalmic Drug Makers: Industry Group
April 9, 2018
- Japan CRO Association Members Deliver Actual 8.1% Sales Surge in 2017
April 5, 2018
- GHIT Fund to Make New Investment of 1.66 Billion Yen for Development of Therapies and Vaccines
March 30, 2018
- 100 Infusion Products Got Price Raises under Unprofitability Re-Pricing, but Drastic Pricing Reform Still Necessary: IV Solution Society
March 26, 2018
- Americas Chief James Robinson Leaves Astellas, What Will Happen to PhRMA Treasurer Seat?
March 20, 2018
- Annual Re-Pricing Key Focus Issue for Japan Pharma Trade Group in FY2018
March 16, 2018
- Hodanren Opposes Generic Use Requirement for Welfare Recipients
February 23, 2018
- JPMA to Compile Counterproposal for New PMP Scheme ASAP
February 16, 2018
- Astellas Becomes 1st Japan Maker to Join PhRMA Leadership
February 14, 2018
- Private Univ. Group Encourages “Single-Product, Single-Price” Deals in Response to New Distribution GL, Tougher Medical Fee Cut Rules
February 9, 2018
- “Unprecedented Reforms to Take Place as a Result of Chuikyo’s Leadership”: JMA Pres. Yokokura
February 8, 2018
- Japan Could Miss Out on Wave 1 of Drug Development, Re-Do and Do Right on PMP: PhRMA
January 30, 2018
- Japan Pharma Leader Says Pricing Overhaul Would Not Expand Drug Lag
January 18, 2018
- Exclude 50 Yen or Lower Price Generics from “Off-Year” Re-Pricing: JGA Chief
January 15, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…